Powered by

Pharmaceutics

The latest articles, press releases and dossiers on pharmaceutics in Baden-Württemberg

  • Article - 31-Jul-2018

    Deafness is one of the most common sensory disorders in the world: in Germany alone, around eleven million people suffer from hearing loss. So far there is no real therapy, the symptoms can only be alleviated to a greater or lesser degree. This is what researchers from the Tübingen-based company Acousia Therapeutics want to change: they have identified drug candidates that can protect sensory hair cells and support their function.

  • Article - 23-May-2018

    Multidrug-resistant bacteria are resistant to many existing antibiotics and can be difficult to treat. There are increasing numbers of them worldwide. Although novel antibiotics are being developed, there are far too few of them to tackle the rise of multidrug-resistant bacteria. In Eastern Europe, doctors have been treating bacterial infections with viruses that infect bacteria, so-called bacteriophages, for almost 100 years.

  • Article - 05-Apr-2018

    It can take many decades before promising research results become therapies that have a positive effect on cancer patients. Most research projects go adrift somewhere between the laboratory and the bedside in the so-called "valley of death". Projects carried out at the DKFZ show that translational cancer research actually works.

  • Article - 21-Mar-2018

    At present, potential new drugs have to be tested on animals before they can be used on humans. However, results obtained from animals are not always transferrable to the situation in humans, which is why researchers around the world have long been seeking alternatives. Miniature human organs that can be used to test the efficacy of potential human drugs might provide a solution.

  • Article - 21-Feb-2018

    HepaRegeniX, a biotech company founded in 2016, specialises in developing drugs that restore the regenerative capacity of diseased livers. The three founders of the biotech start-up, Prof. Dr. Lars Zender, Prof. Dr. Stefan Laufer and Dr. Wolfgang Albrecht, anticipate starting clinical testing of the first drug candidate in 2019.

  • Article - 14-Feb-2018

    Quite a number of promising drug candidates for the treatment of diabetes are currently in the pharmaceutical pipeline, including innovative drugs that can stimulate the regeneration of insulin-producing pancreatic cells. However, they will have to be safety tested in animals. Scientists from Ulm University Hospital have now begun to develop a pancreatic chip from stem cells.

  • Press release - 13-Feb-2018

    Extends ongoing collaboration with Bill & Melinda Gates Foundation with award of two new grants. CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the awarding of two new grants from the Bill & Melinda Gates Foundation.

  • Article - 07-Dec-2017

    “Stop experimenting – GoSilico” is the motto of a young start-up company from Karlsruhe. The founding team of GoSilico GmbH is causing a furore with a simulation software that would make many laboratory experiments obsolete. The chromatographic separation of biomolecules from organisms, samples and cell cultures can be reliably simulated after just a few starter experiments. This saves time, work, material and costs in pharmaceutical development.

  • Article - 06-Nov-2017

    Peptide- and protein-based drugs like those used for treating diabetes, cancer and autoimmune diseases cannot be administered orally. This is because these biomolecules degrade in the gastrointestinal tract, thus preventing them from reaching their target site in the body. Protein- and peptide-base drugs therefore have to be administered by way of injection, which is comparatively complicated and painful. However, a start-up company called Heidelberg Delivery Technologies GmbH has now developed an innovative technology that makes taking medicines as easy as eating gummy bears.

  • Article - 19-Jun-2017

    Realistic alternatives to animal testing are more in demand than ever, especially in the drug development field. One possible solution is 3D cell cultures that possess the characteristics of the tissue from which they originate. Such systems were already developed at the Karlsruhe Institute of Technology (KIT) many years ago. Due to the huge demand for such systems, Prof. Dr. Eric Gottwald and two of his colleagues founded a company called 300MICRONS GmbH, which develops and markets 3D cell culture systems for different applications. The company will soon be able to produce large quantities of such cell culture systems.

  • Article - 07-Jun-2017

    On 23rd May 2017, Pfizer officially opened a modern continuous manufacturing plant in Freiburg, thus setting a new technological standard for tablet production. A groundbreaking ceremony to inaugurate Pfizer’s new PCMM plant was held at the same time. Pfizer is investing around 50 million euros in the Freiburg facility.

  • Article - 02-Jun-2017

    SÜDPACK Verpackungen is a qualified supplier of plastic films to the biopharmaceutical industry. The company is the leading European manufacturer of packaging products for the food industry and also offers its expertise to the biopharmaceutical industry. In 2011, SÜDPACK created an exclusive cooperation partnership with Sartorius Stedim Biotech, a global technology provider for the pharmaceutical biotech industry, which has now been extended before its end date.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/pharma/